

MARKET RELEASE (ASX: CTE) 9 May 2024

Chairman's Update, Board Change, and Corporate Presentation

Having joined as Chairman of Cryosite Limited ACN 090 919 476 (ASX: CTE) (**Cryosite** or **Company**) in December 2023, I undertook a six-month review of the Company, its people, and operations.

I am delighted to share the findings of this process with shareholders as the Company accelerates its phase of growth.

Cryosite's business continues to perform strongly.

In recent weeks, Cryosite has received positive feedback from key customers. Cryosite is currently working with these key customers towards executing renewals of their existing agreements with the Company. We will keep the market informed of material developments.

Cryosite remains strongly cash flow positive (\$4.7m Cash Balance as at 30 April 2024 unaudited) with all business segments operating in a very positive manner.

As you know, on 06 October 2023, the Company paid a 1.5 cent per share dividend and on 29 February 2024, the Company paid a 5 cent per share return of capital.

The Company's outlook remains positive, and it is our intention to pay further dividends this year once our financials have been audited for FY24.

Looking forward, we are positioned for growth and aligned with market trends with plans to increase our storage capacity by December 2024.

Our focus is on expanding into the emerging fields of biological storage and cell & gene therapy depot services, while continuing to support our current clinical trials clients in meeting their evolving needs.

Cryosite is pleased to announce the appointment of Mr Scott Thomas as a Director of the Company.

Scott has strong experience in the financial services profession both in Australia and the United Kingdom having held senior roles at ANZ and Vanguard Investments. Scott holds a Diploma of Financial Strategy (Oxford University), a Master of Applied Finance (Macquarie University) and a Bachelor of Commerce (The University of Melbourne).

Cryosite is also pleased to release its Corporate Presentation which has been published to the ASX and can be found on our website: https://cryosite.com/blogs/.

This presentation provides shareholders with an overview of Cryosite's unique business segments, extensive accreditations, specialised facility and operations, strong competitive advantage, historical performance, and opportunities for growth.

ENDS



This announcement has been authorised for release by the Board of Directors of Cryosite Ltd.

For more information, please contact:

Mark Kerr Chairman +61 041 833 8784